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Running Title: COVID-19 head and neck recommendations 
  
Abstract 
 
Introduction 
Due to the unprecedented disruption of health care services by the COVID-19 pandemic, the 
American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy 
and Oncology (ESTRO) identified an urgent need to issue practice recommendations for 
radiation oncologists treating head and neck cancer (HNC), in a time of heightened risk for 
patients and staff, and of limited resources. 
 
Methods 
A panel of international experts from ASTRO, ESTRO and select Asia-Pacific countries 
completed a modified rapid Delphi process. Questions and topics were presented to the group, 
and subsequent questions developed from iterative feedback. Each survey was open online for 
24 hours, and successive rounds started within 24 hours of the previous round. The chosen 
cutoffs for strong agreement (≥80%) and agreement (≥66%) were extrapolated from the RAND 
methodology. Two pandemic scenarios: early (risk mitigation) and late (severely reduced 
radiotherapy resources) were evaluated. The panel developed treatment recommendations for 
five HNC cases. 
 
Results  
In total, 29/31 (94%) of those invited accepted, and after a replacement 30/30 completed all 
three surveys (100% response rate). There was agreement or strong agreement across a 
number of practice areas including: treatment prioritisation, whether to delay initiation or 
interrupt radiotherapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation 
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dose-fractionation schedules and use of chemotherapy in each pandemic scenario), 
management of surgical cases in event of operating room closures, and recommended 
adjustments to outpatient clinic appointments and supportive care. 
 
Conclusions 
This urgent practice recommendation was issued in the knowledge of the very difficult 
circumstances in which our patients find themselves at present, navigating strained health care 
systems functioning with limited resources and at heightened risk to their health during the 
COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC 
treatments continue, to save lives and for symptomatic benefit. 
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Practice recommendations for risk-adapted head and neck cancer radiotherapy during 
the COVID-19 pandemic: an ASTRO-ESTRO consensus statement 
 
Introduction 
 
The coronavirus (SARS-CoV-2) outbreak is considered a global pandemic by the World Health 
Organization.1 Most infected people develop a mild respiratory illness, but based on an early 
census from the U.S. Centers for Disease Control, 20-30% of persons aged ≥ 45 years require 
hospital admission, and fatality rates range from 10-17% in persons aged ≥ 85 years, 3-11% 
among persons aged 65-84 years, and 1-3% among persons aged 55-64 years.2 Those with 
cancer or receiving treatment for cancer are at enhanced risk of serious morbidity, including the 
need for ventilator support or death (HR 3.56, [95% CI, 1.65 to 7.69]).3  The pandemic has 
strained cancer services, with routine outpatient appointments cancelled, elective surgeries 
postponed and resources diverted to the front line. 
  
For the oncology clinician wishing to offer palliative systemic therapies there is a Hobson’s 
choice: a high symptom burden from the cancer without treatment or an increased risk of a 
more imminent death from SARS-CoV-2 infection resulting from the exposure and stress of 
therapy. For curative-intent treatments, there are parallel and specific challenges facing the 
head and neck (HN) oncologist: (i) operating room closures, with increased requirement for non-
surgical treatments, (ii) an altered risk-benefit ratio of chemotherapy and radiotherapy due to 
increased susceptibility for SARS-CoV-2 infection, (iii) a need to suppress coronavirus spread 
by minimizing travelling of patients for daily treatments and the exposure of hospital and 
radiotherapy staff, and (iv) a shortage of radiotherapy resources due to staff sickness or leave 
for family care entailing allocation of resources and triage of patients. The use of 
hypofractionated radiotherapy (radiation schedules that are shorter overall but give a larger 
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dose per treatment) could help address the latter two concerns, but these regimens may be 
unfamiliar to many radiation oncologists, and there is a risk of inappropriate application if these 
fall outside current international guidelines. 
  
Due to this unprecedented disruption of health care services by the COVID-19 pandemic, the 
American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy 
and Oncology (ESTRO) identified an urgent need to issue practice recommendations for 
radiation oncologists treating head and neck cancer (HNC), in a time of heightened risk for 
patients and staff, and of limited resources. 
  
 
Methods 
  
With endorsement of the ASTRO and ESTRO executive committees, a panel of international 
experts was identified to provide practice recommendations for HNC during the COVID-19 
pandemic. Panellists were nominated in equal numbers from the two societies with select 
representation from a few affected Asia-Pacific countries. A modified rapid Delphi process was 
used to develop consensus recommendations. A systematic literature review was not performed 
due to the urgency and lack of information on the conduct of cancer treatment related to the 
COVID-19 pandemic. The organizers (DT, SY, DP, MG) presented the initial topics and 
questions to the group by electronic survey and subsequent questions were developed based 
on iterative feedback from the panellists. Questions were not asked again after agreement was 
reached. Each survey was open online for 24 hours and successive rounds started within 24 
hours of the previous round. The chosen cutoffs for strong agreement (≥80%) and agreement 
(≥66%) were extrapolated from RAND methodology.4 
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Two scenarios, both of current and global relevance to the COVID-19 pandemic, were 
evaluated: 
  
● Early COVID-19 pandemic scenario 1 – risk mitigation, given the potential for: (i) patient 
and/or staff infection due to repeat hospital visits, (ii) risk of more serious infection in 
those receiving radiotherapy and/or chemotherapy, and (iii) negative impact on strained 
healthcare resources from the management of the expected severe toxicities associated 
with intensive chemo-radiotherapy. 
● Later COVID-19 pandemic scenario 2 – severely reduced radiotherapy resources: the 
additional consideration of a lack of resources, whereby some patients are unable to 
receive radiotherapy. 
 
The panel was asked to develop treatment recommendations for five common clinical cases of 
head and neck squamous cell carcinoma (HNSCC): 
 
1: Oropharyngeal SCC, T2 with multiple ipsilateral nodes < 3 cm, M0; this was subdivided into:  
1a: p16 negative (OP-) and  
1b: p16 positive (OP+) 
2: Laryngeal glottic SCC, T1bN0M0 (GLOT) 
3: Laryngeal SCC, T3N1M0 with impaired vocal cord mobility (LX) 
4: Metastatic hypopharyngeal SCC, T4N1M1 – obstructed, bleeding, with several lung 
metastases (HXpal) 
5: Resected oral cavity SCC, pT2pN2aM0; this was subdivided into: 
5a: with positive margins (OC+) and   
5b: with close but clear 3mm margins (OC-) 
  
 6 
Supplementary questions concerned the conditions for delaying or interrupting radiation or 
chemotherapy for intercurrent SARS-CoV-2 infection, treatment prioritisation in case of severely 
limited resources, management in case of surgical operating room closures, and how HN 
oncologists are adjusting clinics to account for the attendant risks. For all cases, we assumed a 
representative HNC patient fit for chemotherapy and/or radiotherapy. 
 
This consensus statement was developed through an agreement between the ASTRO and 
ESTRO, although given the urgency and differences in the societies’ usual development 
processes, adjustments to the societies’ usual procedures were allowed. The process was 
further endorsed by the Head and Neck Cancer International Group (HNCIG). Waiver of 
consent and exempt status was conferred by the University of California, San Francisco 
Institutional Review Board (#20-30633). 
  
Results 
  
In total, 29/31 (94%) of those invited accepted, and after a replacement nomination by ESTRO, 
30/30 completed all three surveys (100% response rate). In the respective rounds, there were 
80, 35 and five questions, taking on average a total of 73, 25 and five minutes to complete. The 
list of questions and panellists’ responses are included in Appendix 1. 
  
Treatment prioritisation 
 
Panellists were asked if certain cases should be postponed in either the early or late pandemic 
scenario. There was strong agreement (for cases of OP-, OP+, LX, HXpal, OC+) or 
agreement (GLOT) not to postpone the initiation of HNSCC radiotherapy by more than 4-6 
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weeks in both the early and late scenarios. For OC- in the late scenario, there was no 
consensus. 
 
Panellists were then asked to prioritise the cases. Compared to all other types of cancer within 
one’s department requiring radiotherapy, there was strong agreement that OP-, OP+, and LX 
were very high (top 20%) or high (top 20-40%) priority. On average, GLOT and OC+ were also 
deemed high priority, while HXpal was of average (40-60%) priority. OC- was lower priority, and 
some (23%) would omit radiotherapy in case of severely limited radiotherapy capacity. 
  
In a situation of severely reduced resources, we further asked for these cases to be ranked in 
order of treatment priority against each other. These were ranked by the panel from high to low 
as: OP+, OP-, LX, OC+, GLOT, HXpal, OC-. To further understand the trade-offs between 
treatment urgency and clinical priority, we asked respondents to set a policy by which a group of 
20 patients would be treated before the other group could start. In this situation of policy 
determination, panellists prioritised LX over OP- (62%), OC+ over HXpal (63%), and HXpal over 
GLOT (73%). 
  
Panellists were finally asked to prioritise factors that would matter most in starting radiotherapy 
either within the next one week or next 2-3 weeks. These rankings are shown by the highest to 
lowest weighted average from top to bottom (Figures 1a-b). In both scenarios of early and late 
pandemic, the three factors of active SARS-CoV-2 infection, symptomatic benefit, and potential 
for cure (as opposed to the specific % likelihood of cure) were the most important in triage for 
radiotherapy over the next one week (Fig. 1a). With an additional week or two of time before 
starting, active SARS-CoV-2 infection fell to the second highest weighted position behind 
symptomatic benefit (Fig. 1b). 
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COVID-19 Practice Recommendations: Treatment Prioritisation  
Do not postpone the initiation of HNSCC 
radiotherapy by 4-6 weeks 
Strong agreement  
HNSCC radical radiotherapy is high or very 
high priority  
Strong agreement 
HNSCC post-operative radiotherapy for 
involved margins is high priority 
Agreement 
HNSCC post-operative radiotherapy for minor 
risk factors is lower priority 
Agreement 
 
Intercurrent SARS-CoV-2 infection 
  
In the case of a patient testing positive for SARS-CoV-2 infection, there was strong agreement 
(OP, GLOT, OC) or agreement (LX, HXpal) to delay the initiation of radiotherapy until the 
patient had recovered. However, for all cases there was initially agreement not to interrupt 
radiotherapy (except for HXpal, where a single fraction could be used). We therefore sought to 
better understand the recommendation not to interrupt radiotherapy, and the interaction of this 
decision with SARS-CoV-2 symptom severity and timing during radiotherapy. 
  
Panellists were instructed to assume that appropriate personal protective equipment (PPE) 
would be available and best practices would be implemented, such as treating the patient at the 
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end of the day in a designated vault, limiting exposure by utilizing minimal staff and properly 
sanitizing the vault.  
 
Under assurance of these conditions, for patients testing positive with mild symptoms (cough 
but normal activity level), 63% of the panel voted to continue radiotherapy, 17% would only 
interrupt in the first or second week of radiotherapy, and 20% would interrupt in any week of 
radiotherapy until the patient recovered. In other words, there was strong agreement to 
continue radiotherapy in those with SARS-CoV-2-related mild symptoms who had completed 
more than two weeks of treatment. On the other hand, there was also strong agreement 
among panellists to interrupt radiotherapy in any SARS-CoV-2+ patient demonstrating more 
severe symptoms (cough, chest pain, and trouble breathing at rest requiring oxygen support) 
until the patient had fully recovered. Different centers reported varying policies on deciding 
when a SARS-CoV-2+ patient would be able to return including repeat negative testing as well 
as 10-14 day waiting periods. 
 
For the minority who would interrupt radiotherapy even for mild symptoms, the top stated 
reasons included: (i) concern for worsening the patient’s respiratory and general condition, (ii) 
increased likelihood of emergency admission and/or need for feeding tube insertion and (iii) risk 
of infecting other patients and staff. A few panellists expressed that protection of staff and other 
patients should be prioritised over treatment of a single patient, if unavailability of resources 
would endanger the many for the one.  
  
COVID-19 Practice Recommendations: Intercurrent SARS-CoV-2 infection 
For patients testing positive for SARS-CoV-2 infection:                                   
Delay initiation of radiotherapy until recovery Strong agreement 
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+/- SARS-CoV-2 test is negative     
Do not interrupt radiotherapy for mild SARS-
CoV-2-related symptoms    
Agreement 
 
Do not interrupt after week 2 of radiotherapy 
for mild SARS-CoV-2-related symptoms   
Strong agreement 
Do interrupt radiotherapy for severe SARS-
CoV-2-related symptoms     
Strong agreement 
 
 
Case-specific radiotherapy and chemotherapy practice 
  
For each case, we asked participants to provide their center’s standard radiotherapy dose-
fractionation and how (if at all), this would be varied for scenarios of risk mitigation or severely 
restricted radiotherapy capacity (Table 1). In scenario 1 of early pandemic, there was strong 
agreement (OP and OC) or agreement (GLOT and LX) to stay with the same radiotherapy 
dose-fractionation. There was no consensus for HXpal. In scenario 2 of late pandemic, there 
was strong agreement to use a more hypofractionated schedule for all of the cases compared 
with the average standard approach. 
 
Panellists stated that their usual standard concomitant chemotherapy schedules were cisplatin 
at 80-100 mg/m2 every 3 weeks (60%) and cisplatin at 30-40 mg/m2 once a week (40%). In 
early pandemic, there was strong agreement to continue the use of chemotherapy for all 
relevant cases where it would be applied (OP-, OP+, LX, OC+; Table 2) and agreement not to 
alter the schedules they used in standard practice. However, numerous panellists stated they 
would consider switching from high-dose to weekly cisplatin. In the late pandemic setting, there 
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was agreement to omit chemotherapy for OP+, and the majority (63%, near-agreement) would 
omit chemotherapy for HNC in general in this situation. 
  
Given the recommendations to use more hypofractionated radiotherapy schedules, we sought 
to understand the maximum dose per fraction that panel members considered safe and 
acceptable to use with concomitant chemotherapy. There was agreement favoring use of 
concomitant chemotherapy only with conventional or mildly hypofractionated radiotherapy of 
≤2.4 Gy / fraction (52%: 2.0-2.2 Gy / f; 21%: 2.2-2.4 Gy / f; 24%: 2.4-2.6 Gy / f; 3%: 2.6-2.8 Gy / 
f). 
  
Of note, most panellists (63%, near-agreement) stated they did not consider induction 
chemotherapy to be a standard treatment for LX. A few (10%) supported induction as a 
standard treatment and a minority (27%) supported its consideration as a temporizing measure 
in times of pandemic. There was in the end a majority (63%) recommending against use of 
induction chemotherapy in either of the pandemic scenarios. Several panellists expressed 
concern about the SARS-CoV-2-specific risk that could be incurred from an extended period of 
myelosuppression. 
 
COVID-19 Practice Recommendations: Radiotherapy and chemotherapy practice 
In scenario 1, risk mitigation:         
Do not alter standard HNSCC radical 
radiation dose-fractionation            
Agreement 
Continue to use concomitant chemotherapy           Strong agreement 
Continue to use the standard concomitant Agreement 
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chemotherapy schedule        
Do not use induction chemotherapy for 
locoregionally advanced larynx SCC 
Majority, near-agreement 
 
 
In scenario 2, risk mitigation with severely reduced radiotherapy capacity: 
Use a hypofractionated radiation schedule    
  
Strong agreement 
Reserve concomitant chemotherapy for use 
with conventional or mildly hypofractionated 
radiotherapy (≤ 2.4 Gy / f)    
Agreement 
Do not use induction chemotherapy to delay 
initiation of treatment     
Majority, near-agreement 
 
 
Operating room closures and the management of surgical cases 
  
In many afflicted regions around the world, operating theatre capacity has been curtailed or in 
severe pandemic scenarios, discontinued. However, many HNC are traditionally treated with 
primary surgery. In the case of absolute operating room closure, we asked about the panellists’ 
recommended non-surgical treatment strategy for five cases typically managed by primary 
surgery. 
 
A: Oral Tongue SCC, Radical radiotherapy   Agreement 
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T2N0M0   
B: Oral Tongue SCC, 
T3N2bM0 
Radical chemo-radiotherapy Strong Agreement 
 
C: Laryngeal SCC, 
T4aN2bM0, with 
tracheostomy  
Radical chemo-radiotherapy  Agreement 
 
D: Hard palate adenoid cystic 
carcinoma, T2N0M0   
50% radical RT, 47% 
surveillance   
No agreement  
E: Sinonasal maxilla SCC 
T4aN1M0    
Radical chemo-radiotherapy    Strong Agreement 
 
In response to this question, a few panellists commented that they would not wait more than 2-3 
months for surgery. Therefore, for oral cavity cancers, where primary radiotherapy is less 
effective and more toxic, we specifically asked what amount of time would be acceptable for a 
patient to wait for operating room availability rather than starting radical (chemo-)radiotherapy. 
  
A: Oral Tongue SCC, 
T2N0M0 
Wait up to 8 weeks     Agreement 
 
B: Oral Tongue SCC, 
T3N2bM0 
Wait up to 4 weeks Strong Agreement 
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A few practitioners commented that in these conditions they might wait longer such as 12 or 6 
weeks, respectively, to obtain surgery for these two cases. 
 
COVID-19 Practice Recommendations: Operating room closures and surgical cases 
Where faced with operating theatre closures and no capacity for HNC surgery: 
(Chemo-)radiotherapy should be used for 
locoregionally advanced HNSCC 
Agreement 
Non-treatment is acceptable in certain cases 
of slow-growing cancers   
No agreement 
 
For early oral cavity cancers, consider waiting 
for surgical capacity, if this is predicted to be 
available within 8 weeks, and in this situation 
check on the patient every few weeks for 
progression 
Agreement 
For locoregionally advanced oral cavity 
cancers, consider waiting for surgical 
capacity, if this is predicted to be available 
within 4 weeks 
Strong agreement 
 
Adjustments to outpatient clinic appointments and supportive care 
  
During the pandemic, there was strong agreement to modify the routine weekly in-person (face 
to face, in the same room) on-treatment reviews for patients receiving radiotherapy. There was 
also agreement to change the usual practice of conducting all new patient consultations in 
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person. For both situations, there was no consensus approach, as some (23%) had stopped in-
person reviews altogether and others had reduced the frequency of in-person visits, replacing 
them with telephone (50%) or video (26%) consultations. A few panellists commented on 
concomitant reduction of dental, nutrition, or speech pathology services. 
  
Panel members were in strong agreement not to increase the use of prophylactic placement of 
percutaneous endoscopic gastrostomy (PEG) feeding tubes; some commented that 
interventional radiology services were unavailable due to pandemic and PEG use was actually 
decreased. Over half (53%) of the panellists were no longer performing aerosol-generating 
procedures within the radiotherapy department (tracheostomy care, airway suctioning, flexible 
fiberoptic nasopharyngoscopy, nasogastric tube insertion). 
   
COVID-19 Practice Recommendations: Appointments and Supportive Care 
Where possible, reduce in-person (face to face, in the same room) consultations and replace 
with telephone or video for: 
Routine weekly on-treatment reviews  Strong agreement 
 
New patient consultations  Agreement 
 
Discussion 
  
The aim of this ASTRO-ESTRO practice recommendation was to provide urgent support for 
clinicians faced with managing HNC during the COVID-19 pandemic. There are a number of 
substantial recommendations, structured around typical cases in distinct pandemic scenarios, 
but treatment decisions in the real world must take into account all of the clinical factors relevant 
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at the time. These decisions are informed by local and national policies, and must be made 
within political, financial and regulatory frameworks. On a practical level, the ability to implement 
hypofractionated radiotherapy schedules will depend on the circumstances of the particular 
radiotherapy department, and the capability and capacity to do so (for example, knowledge of 
altered fractionation, critical structure dose constraints, and dosimetrist and physicist 
resources). 
  
In the early, risk-mitigation scenario, neither the potential benefits of using hypofractionated 
radiotherapy to reduce frequency of patient attendance, nor the omission of concomitant 
chemotherapy to reduce risk of immunosuppression or treatment complications, were deemed 
sufficient justification to alter standard practices for locoregionally advanced HN cancer. 
However, our scenarios described a patient fit for a combined-therapy regimen. Patient-specific 
factors (such as age, fitness, comorbidities) were not addressed in this study. It has been 
recognized that the benefit of concomitant chemotherapy decreases with increasing age 
(especially for those >60 years’ old).5 Therefore, for older patients or those with comorbidities 
who are at higher risk of more serious SARS-CoV-2 infection,6 and for whom concomitant 
chemotherapy will have less benefit, the use of chemotherapy should be restricted. 
 
In the later scenario of severely reduced capacity (where some patients would need to go 
without radiotherapy), there was strong support for hypofractionated radiotherapy. For early 
larynx cancer (T1N0), 50 Gy / 16f was most commonly recommended,7,8 and there are data for 
55 Gy / 20f in T2N0 disease.9,10 There is limited evidence to support the use of hypofractionated 
radical radiotherapy over 4-5 weeks for locoregionally advanced disease, but panellists 
suggested schedules including:  55 Gy / 20f,11,12,13,14 62.5-64 Gy / 25f,15,16 and 54 Gy / 18f.17,18 
Most would not use concomitant chemotherapy in this setting, and there was agreement to 
restrict concomitant chemotherapy to schedules of ≤ 2.4 Gy / f. While there are data to support 
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the use of concomitant platinum chemotherapy with higher doses per fraction,12,13,15 panellists 
expressed reservations about the potential lack of benefit (for example, no apparent local 
control or overall survival advantage from the combination of chemotherapy with accelerated 
radiotherapy),19,20 and the risk of increased acute and late toxicities. 
  
It is important to recognize the continuum between the early and late scenarios described in this 
statement. The prevalence of SARS-CoV-2 infection in a given community may reach a point 
whereby risk-mitigation strategies such as shorter fractionation schemes and the omission of 
concurrent chemotherapy must be considered prior to the actual onset of severely reduced 
capacity. Unfortunately, because predictors of how long a pandemic condition will last in a given 
geographic area are not exact, individual clinicians and policy-makers are forced to make 
complex decisions with considerable uncertainty; this is in fact a limitation on many 
recommendations in this consensus statement due to marked variability in the extent, duration, 
and characterisation of pandemic conditions across nations and regions. Decision-making within 
the context of continually evolving pandemic conditions is further challenged by the prolonged 
nature of a course of chemoradiation in the HNC population.  
 
Panellists also wished to address the conditions under which a SARS-CoV-2+ patient might be 
treated. As resources permit, clinicians should adhere to formal, pre-specified screening and 
viral testing algorithms for HNC patients, because mucosal symptoms related to HN radiation 
may mimic mild infectious symptoms. For patients developing mild symptoms during 
radiotherapy and testing positive for SARS-CoV-2 infection, there was agreement not to 
interrupt treatment, especially if the patient had already completed the first two weeks of 
radiotherapy due to more limited ability to re-irradiate to a curative-intent dose and concerns 
about accelerated tumor repopulation later in the treatment course. The minority who wished to 
interrupt radiotherapy even for mild SARS-CoV-2-related symptoms cited concerns about the 
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tolerability of treatment and the increase in exposure of staff and resource burden on the 
department and hospital. On the other hand, there was near-unanimous agreement that a 
patient highly symptomatic with SARS-CoV-2 infection should be interrupted. 
  
In the later pandemic situation of severely reduced radiotherapy resources, decisions about 
treatment prioritisation are required. When asked to determine the priority for each case 
compared with all other cancers and then amongst only the HNC cases, the average rankings 
were consistent, from highest to lowest priority: OP+, OP-, LX, OC+, GLOT, HXpal, OC-. 
However, when further tested as direct trade-offs choosing whether to start groups of 20 
patients over the others, there were two areas of divergence. First, in these larger-scale policy 
terms, it was agreed HXpal should be prioritised over GLOT with the rationale that: (i) the 
treatment course could be delivered expediently by a single radiation fraction (note the increase 
from 4% to 30% of panellists who would use a single fraction in these late pandemic 
circumstances), which would result in important symptomatic benefit, and (ii) GLOT could wait 
for a period of time to start radiotherapy without risk of significant progression or change in the 
chance of cure. This approach is in keeping with the earlier finding where postponement of 
GLOT by 4-6 weeks was acceptable to more than 20% of panellists. Second, the majority (62%) 
now agreed LX should be treated before OP-. This was important to prevent potential airway 
obstruction (i.e., for symptomatic benefit), where both cases had a similar chance of cure. This 
preference was consistent with our finding that symptomatic benefit and chance of cure were 
two of the top three factors for panellists in determining which group of patients should start 
treatment within a week or 2-3 weeks in the face of severely reduced radiotherapy capacity. In 
terms of factors conditioning whether to initiate radiotherapy, the third most important factor was 
SARS-CoV-2 status, which reflects the strong agreement to delay the start of treatment in 
patients testing positive for SARS-CoV-2 infection. 
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An unfortunate consequence of the COVID-19 pandemic is the closure of operating rooms, due 
to a lack of protective equipment to counteract increased exposure risk, and redeployment of 
anesthesiologists and ventilators to critical care. There was consensus that HNC cases normally 
managed by primary surgery should generally be treated with radical (chemo-)radiotherapy 
rather than have no treatment. However, for cancers of the oral cavity, where radiotherapy is 
less effective and more toxic than surgery, there was agreement that waiting for up to 8 and 4 
weeks for surgery was acceptable for T1-2 cancers and T3-4 cancers, respectively, with close 
clinical surveillance every few weeks to monitor for clinical progression.  
 
A major effect of the COVID-19 pandemic is a shift in the risk-benefit ratio which typically 
governs HNC management. In the face of severely reduced resources, unaccustomed trade-
offs may become necessary with the consequence of being forced to consider treatments that 
could carry a higher risk of late effects (hypofractionation) or could be suboptimal (without 
chemotherapy, nonsurgical), to ensure safety and therapeutic benefit for the greatest number of 
persons. These newly developed practice recommendations provide a global consensus and 
basic harmonisation of approach in the face of limited clinical data to direct these difficult, 
unfamiliar decisions. One tangible benefit already achieved was the rapid sharing and 
comparison of hypofractionation schedules considered “acceptable” by global HNC experts in 
times of extreme crisis such as COVID-19.  
 
This urgent practice recommendation was issued in the knowledge of the difficult circumstances 
in which our patients find themselves at present, navigating strained health care systems 
functioning with limited resources and at heightened risk to their health from SARS-CoV-2 
infection. The aim of this consensus statement is to ensure that high-quality HNC treatments 
continue, to save lives and for symptomatic benefit. The process was unusual in that several 
members of this panel participated even as they continued to deliver treatments facing serious 
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personal risks to themselves. This statement attempts to address the immediate impacts of the 
COVID-19 pandemic on HNC clinical practice; an understanding of future consequences 
(impacts on clinical research and scientific advance, health care systems’ financial standing, 
health and psychological consequences for practitioners and patients) will require continued 
attention. 
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Figure 1a. (left panel) In scenario 2 (severely reduced radiotherapy resources), which are your 
top three factors to inform the triage (prioritisation) of patients with head and neck cancer to 
start this week? Factors are ordered from highest to lowest weighted. 
 
Figure 1b. (right panel) In scenario 2 (severely reduced radiotherapy resources), which are your 
top three factors to inform the triage (prioritisation) of patients with head and neck cancer to 
start within 2-3 weeks? Factors are ordered from highest to lowest weighted. 
 
Table 1. Fractionation schedules for for five clinical cases: standard, early pandemic and late 
pandemic recommendations. 
Clinical case Standard approach: % 
agreement and 
favoured schedules* 
Scenario 1 
Early Pandemic -       
risk mitigation                                     
  
                             
Change from 
standard: % 
agreement and 
favoured schedules* 
Scenario 2 
Late Pandemic -                 
severe shortage of 
radiotherapy capacity 
 
Change from standard: 
% agreement and 
favoured schedules* 
1: Oropharynx 
SCC 
T2N2bM0 p16 
negative 
(OP-) 
2.0-2.2 Gy / f (100%)  
(strong agreement)         
 
70 Gy / 35f (63%)  
70 Gy / 33f (17%) 
65-66 Gy / 30f (13%)                        
  
No change       
(strong agreement) 
Hypofractionated       
2.41-3.0 Gy / f (70%)                       
(strong agreement) 
 
55 Gy / 20f (30%) 
54 Gy / 18f (7%) 
62.5-64 Gy / 25f (7%) 
2: Larynx SCC 
T1bN0M0 
(GLOT) 
2.0-2.4 Gy / f: 80% 
(strong agreement) 
 
63 Gy / 28f (52%) 
70 Gy / 35f (14%) 
66 Gy / 33f (10%) 
50 Gy / 16f (7%) 
55 Gy / 20f (7%) 
  
No change 
(agreement) 
Hypofractionated     
2.41-3.2 Gy / f (70%)  
(strong agreement)  
 
50 Gy / 16f (30%)  
3: Larynx SCC 
T3N1M0 
(LX) 
2.0-2.2 Gy / f: 97%      
(strong agreement) 
             
70 Gy / 35f (63%) 
No change 
(agreement) 
Hypofractionated          
2.21-2.8Gy/f (80%)             
(strong agreement) 
 
55 Gy / 20f (30%) 
54 Gy / 18f (7%) 
4: Hypopharynx 
SCC 
Palliative 
(HXpal) 
Various                                         
(no agreement) 
 
30 Gy / 10f (17%) 
44.4 Gy / 12f (17%)* 
20 Gy / 5f (13%) 
32 Gy / 4f (7%) 
8 Gy / 1f (4%) 
 
Various                 (no 
agreement) 
  
8 Gy / 1f (17%) 
44.4 Gy / 12f (13%)* 
20 Gy / 5f (7%) 
 
Hypofractionated 
Various 
(strong agreement) 
 
8 Gy / 1f (30%) 
20 Gy / 5f (20%) 
5: Oral cavity 
SCC 
Post-operative 
pT2pN2aM0, 
involved margins 
(OC+) 
2.0 Gy / f: 87%    
(strong agreement) 
 
66 Gy / 33f (53%) 
60 Gy / 30f (30%) 
  
No change       
(strong agreement) 
Hypofractionated 
Various 
(strong agreement) 
  
50 Gy / 20f (30%)   
62.5 Gy / 25f (10%) 
   
SCC: squamous cell carcinoma; Gy/f: Gray/fraction; % of panellists in agreement with 
dose/fraction range, followed by listing of the most commonly cited schedules arranged by % of 
panellists giving that response (latter does not add up to 100%). 
*Panellists called this schedule “quad shot” but the exact schedule can vary; the most common 
version is 3.7 Gy given twice daily for 2 days, repeated for 3 cycles. 
 
Table 2. Chemotherapy recommendations: standard, early pandemic and late pandemic 
approaches. 
  Standard approach Scenario 1 
Early Pandemic -       risk 
mitigation                                         
                                   
 
 
Standard therapy: % 
endorsement 
Scenario 2 
Late Pandemic -                 
severe shortage of 
radiotherapy 
capacity 
 
Standard therapy: % 
endorsement 
1: Oropharynx 
SCC 
T2N2bM0 p16 
negative 
(OP-) 
Concomitant 
chemotherapy 
  
Yes: 93% 
No: 7% 
(strong agreement) 
Yes: 50% 
No:  50% 
  
1b: Oropharynx 
SCC 
T2N2bM0 p16 
positive 
(OP+) 
Concomitant 
chemotherapy 
  
Yes: 87% 
No: 13% 
(strong agreement) 
Yes: 23% 
No:  77%         
(agreement) 
3: Larynx SCC 
T3N1M0 
(LX) 
Concomitant 
chemotherapy 
Yes: 83% 
No: 7% 
(strong agreement) 
Yes: 40% 
No:  60% 
  
5: Oral cavity SCC 
pT2pN2aM0, 
involved margins 
(OC+) 
Concomitant 
chemotherapy 
  
Yes: 94% 
No: 6% 
(strong agreement) 
  
Yes: 50% 
No:  50% 
  
SCC: squamous cell carcinoma. 
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